03046nas a2200361 4500008004100000022001400041245017300055210006900228260001600297300001000313490000800323520194100331653000902272653002202281653001402303653002502317653001102342653002402353653001402377653001202391653004902403653003302452653000902485653002402494653001702518100001402535700001502549700001702564700002502581700002402606700001902630856003502649 2005 eng d a0008-543X00aProstate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.0 aProstate carcinoma incidence in relation to prediagnostic circul c2005 Jan 01 a76-840 v1033 a

BACKGROUND: There have been several epidemiologic studies investigating the association between circulating levels of insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and insulin in relation to the risk of prostate carcinoma, with conflicting results. To examine this issue further, the authors conducted a nested case-control study within the Cardiovascular Health Study cohort.

METHODS: In men who were diagnosed with prostate carcinoma (cases) between 1990 and 1999 (n=174), the levels of IGF-I, IGFBP-3, and insulin were measured on blood samples that were obtained 1-9 years prior to diagnosis (mean, 3.4 years). Similar measurements were made on 174 male participants without prostate carcinoma (controls) who were matched to cases based on the year blood was drawn, survival until the date of diagnosis, race, and age.

RESULTS: Relative to the men with IGF-I levels in the first (lowest) quartile of the distribution, the risk of prostate carcinoma for men in the second, third, and fourth (upper) quartiles were 0.77 (95% confidence interval [95% CI], 0.43-1.38), 0.73 (95% CI, 0.41-1.30), and 0.67 (95% CI, 0.37-1.25), respectively. The results were influenced little by adjustment for levels of IGFBP-3 or, instead, by evaluating the molar IGF-I/IGFBP-3 ratio. An analysis that was restricted to men who had plasma prostate-specific antigen levels <4 ng/mL at the time of the blood draw yielded similar results. The corresponding relative risks for IGFBP-3 were 0.91 (95% CI, 0.49-1.68), 0.47 (95% CI, 0.25-0.94), and 0.65 (95% CI, 0.35-1.20), respectively. The distribution of serum insulin levels in cases and controls were nearly identical.

CONCLUSIONS: The IGF-I level was not associated positively with the risk of prostate carcinoma; however, an increase in the IGFBP-3 level was associated with a modest decrease in risk.

10aAged10aAged, 80 and over10aCarcinoma10aCase-Control Studies10aHumans10aHypoglycemic Agents10aIncidence10aInsulin10aInsulin-Like Growth Factor Binding Protein 310aInsulin-Like Growth Factor I10aMale10aProstatic Neoplasms10aRisk Factors1 aChen, Chu1 aLewis, Kay1 aVoigt, Lynda1 aFitzpatrick, Annette1 aPlymate, Stephen, R1 aWeiss, Noel, S uhttps://chs-nhlbi.org/node/810